Skip to main content
. 2019 Jul 17;11(7):1626. doi: 10.3390/nu11071626

Figure 2.

Figure 2

The comparison of the global (glo)CDR score improvement between the placebo-administered subjects and the anserine/carnosine supplementation (ACS)-administered subjects for the total or APOE4 negative/positive participants. A bar shows the average of the data and ± SEM. * represents p < 0.05 as described in Table 2 and Table 3.